Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.…
Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists
Ocular Therapeutix (NASDAQ: OCUL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 325 employees.
The shares were at 5.570 USD on 20 November 2026, down 47.6% over 52 weeks. Its 52-week range is 5.540 USD to 16.44 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.23B USD.
Ocular Therapeutix reports return on equity of -40.6% and revenue down 11.5% year over year.
It holds more cash than debt, a net cash position of 450.60M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 4 February 2027.